Brammer has an experienced leadership team and exceptional scientific expertise.
Mark R. Bamforth
President and CEO, Founder
In 2015 Mark founded Brammer Biopharmaceuticals, a cell and gene therapy CMO, subsequently merged in March 2016 with Florida Biologix to create Brammer Bio. Previously, Mark founded Gallus BioPharmaceuticals, a premier CDMO delivering clinical and commercial mammalian based biopharmaceuticals which was sold to DPx Holdings B.V. (Patheon) in September 2014. Mark spent 22 years in the UK and USA, running global operations and a pharmaceutical CMO business for Genzyme Corp. His work at Genzyme included supporting cell therapy and gene therapy clinical trials resulting in the first FDA approval of a cell therapy product. Mark began his career as a petroleum engineer, exploring for North Sea oil, then as a chemical engineer in the whisky industry. He serves on the MassBio Board and is a founding trustee of the Saltire Foundation. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.
Steven H. Kasok
Chief Financial Officer (CFO), Founder
Together with Mark, Steve founded Brammer and Gallus. As Chief Financial Officer he has direct responsibility for finance, human resources, information technology, and legal functions. Previously, Steven served as Vice President and Treasurer of Millipore Corporation; Chief Financial Officer of Cabot Supermetals, Treasurer and Business Development Officer at Haemonetics Corp. and a variety of roles within Converse Inc. and GE. Steven earned a B.S. in Finance from Clarkson University and a M.B.A. from Harvard Business School.
Richard O. Snyder, Ph.D
Chief Scientific Officer, Founder
Dr. Snyder was the founder of Florida Biologix, which was spun out of the University of Florida in 2015 and merged to create Brammer Bio. Dr. Snyder has been investigating virus biology, vector development, cGMP manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 30 years, and was a member of teams who developed novel viral vector-based human gene therapies. Dr. Snyder was an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida; an Assistant Professor of Pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his B.A. in Biology from Washington University in St. Louis. Dr. Snyder has authored over 60 publications and 8 US patents.